Figure 5: Infarct Sizes Following Short-Term Ex-Vivo Administration in Nondiabetic Sprague-Dawley Rats
2019-06-11T07:00:22Z (GMT) by
(A) In contrast to the cardioprotective effect of 4-week oral administration of canagliflozin, we found no evidence of infarct reduction with short-term, ex-vivo administration of canagliflozin: infarct sizes of 45 ± 4% versus 38 ± 3% (p = NS, n = 6 per group) in the vehicle control group. (B) There was no difference in the area at risk in either of the treatment groups (DMSO vehicle control versus canagliflozin; p = NS; n = 6 per group). DMSO = dimethyl sulfoxide; other abbreviations as in Figures 1 and 4.